VivoSeq
Oncology

Bladder Urothelial Carcinoma

7

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

Bladder Urothelial Carcinoma is an early-stage landscape with 7 programs across 5 companies. The most active players are Regeneron, Roche, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. 5 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

6/100

Mech. Concentration

25/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

1 program

Phase 2Roche logo

Roche

1 program

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 3U

UroGen Pharma Ltd.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

7programs
Small molecule457%
Monoclonal antibody343%

Modality classified for 100% of 7 pipeline programs.

Analysis

Trial Status

2

clinical trials

Active, not recruiting1 · 50%
Not yet recruiting1 · 50%

Clinical Trials

Trial Activity

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT03775265·475 enrolled
Neoadjuvant STereotActic Body Radiotherapy and Cemiplimab With or Without Fianlimab for Cisplatin-Ineligible or Cisplatin-Declining Patients With Muscle-Invasive Bladder Cancer (NeoSTAR Bladder)
Not yet recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07414992·44 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)